Aurinia Pharmaceuticals Dividend
Dividend criteria checks 0/6
Aurinia Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.7% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$0.54 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Aurinia Pharmaceuticals: The Right Play Now
Aug 24Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
Aug 15Aurinia Pharma Q2 2022 Earnings Preview
Aug 03Aurinia lupus nephritis drug recommended in Europe
Jul 22A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
Jul 04Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval
May 20Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AUPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AUPH's dividend payments have been increasing.
Dividend Yield vs Market
Aurinia Pharmaceuticals Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (AUPH) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.6% |
Industry Average (Biotechs) | 2.7% |
Analyst forecast in 3 Years (AUPH) | n/a |
Notable Dividend: Unable to evaluate AUPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AUPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate AUPH's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AUPH has not reported any payouts.